Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 125

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 125
---
 a negative net working
capital of $0.7 million. At March 31, 2025, we had cash and cash equivalents of $2.9 million. At December 31, 2024, we had total current
assets of $8.0 million and current liabilities of $4.8 million, resulting in net working capital of $3.2 million. We have substantial
future capital requirements to continue our research and development activities and advance our drug candidates through various development
stages. The Company believes these expenditures are essential for the commercialization of its technologies.

Net
cash used in operating activities for the first three months of 2025 was $2.8 million. Net cash used by investing activities was $0.3
million during the first three months of 2025.

25

The
Company will continue to seek additional capital through further public or private equity offerings, debt financing, additional strategic
alliance and licensing arrangements, collaborative arrangements, or some combination of these financing alternatives. If we raise additional
funds through the issuance of equity securities, the percentage ownership of our stockholders could be significantly diluted, and the
newly issued equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we
raise funds through the issuance of debt securities, those securities may have rights, preferences, and privileges senior to those of
our common stock. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative
partners or others, we may need to relinquish rights to certain of our existing or future technologies, drug candidates, or products
we would otherwise seek to develop or commercialize on our own, or to license the rights to our technologies, drug candidates, or products
on terms that are not favorable to us. The overall status of the economic climate could also result in the terms of any equity offering,
debt financing, or alliance, license, or other arrangement being even less favorable to us and our stockholders than if the overall economic
climate were stronger. We also will continue to look for government sponsored research collaborations and grants to help offset future
anticipated losses from operations and, to a lesser extent, interest income.

If
adequate funds are not available through either the capital markets, strategic alliances, or collaborators, we may be required to delay
or, reduce the scope of, or terminate our research, development, clinical programs, manufacturing, or commercialization efforts, or effect
additional changes to